Histamine release from mast cell

The term "histamine release from mast cell" describes the rapid exocytosis (“degranulation”) by which activated tissue-resident immune cells called mast cells expel preformed granules containing large amounts of bioactive substances—including histamine—into surrounding tissues. This occurs most classically when allergens cross-link IgE antibodies bound to high-affinity Fc epsilon RI receptors on the surface of sensitized mast cells; other triggers include certain drugs, venoms, infections, and physical stimuli. Released histamine acts locally via four G protein-coupled receptors (H1R, H2R, H3R, H4R) on various target tissues causing vasodilation, increased vascular permeability (“wheal-and-flare”), smooth muscle contraction/relaxation depending on tissue type, stimulation/itching/pain at nerve endings—and systemically can lead to symptoms ranging from mild allergy through life-threatening anaphylaxis if unchecked. While “histamine release” itself is not a druggable entity per se, multiple steps in this cascade are targeted therapeutically: prevention with anti-IgE therapies; inhibition with cromolyn sodium; blockade downstream with antihistamines; emergency reversal with epinephrine during severe reactions. Monitoring involves measuring tryptase/histaminemia during acute events as biomarkers for diagnosis/prognosis in disorders like MCAS/mastocytosis/allergy syndromes.

Other names

Mast cell degranulationMast cell activationHistamine secretion by mast cells

For drugs targeting this pathway: Blockade of histamine receptors on effector tissues (antihistamines). Stabilization/inhibition of mast cell degranulation (mast cell stabilizers). Neutralization/removal of circulating IgE to prevent FcεRI crosslinking and subsequent degranulation.